港股18A现象级反向并购案:昔日明星股嘉和生物“重生”,亿腾医药或圆梦港股

钛媒体
08 Oct 2024

港股18A创新历史,现首宗反向收购案。10月7日,嘉和生物-B(06998.HK)发布公告称,公司将以合并方式收购亿腾医药集团(以下简称“亿腾医药”),公司的全资附属GenEdd(合并附属公司)将在合并后并入亿腾医药,亿腾医药将作为存续实体并成为公司的全资附属公司。根据合并收购协议,嘉和生物将合共新发18.21亿股股份向亿腾医药的现有股东收购其所有权益。合并完成后,双方股东将会共同持有合并后主体的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10